Effect of Atorvastatin as a Renal Protection in Patients With Systemic Inflammatory Response Syndrome Using Renal Arterial Resistive Index

Minia University

Status and phase: Enrolling; Phase 1

Conditions: Renal Protection

Treatments: Drug: Atorvastatin 40 Mg Oral Tablet; Drug: placebo drug

Study type: Interventional

Funder types: Other

Identifiers

NCT05946122

343/ 8-2022

Details and patient eligibility

About

Offering renal protection in systemic inflammatory response syndrome by atorvastatin

Enrollment: 106 estimated patients

Sex: All

Ages: 25 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients ( male and female) with systemic inflammatory response ( total leucocytic count >12,000 mm3'. temperature >38 C, Heart rate >90 b/min and respiratory rate>20 cycle).

Exclusion criteria

• Hemodynamic instability
• Pre-admission chronic kidney disease.
• Intra-vascular coagulopathy
• Patients with myopathy.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

106 participants in 2 patient groups, including a placebo group

control group

Placebo Comparator group

Treatment:

Drug: placebo drug

Active ( Ator) group

Active Comparator group

Treatment:

Drug: Atorvastatin 40 Mg Oral Tablet